Hextar Pharmaceuticalss Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 22-12-2024
- Paid Up Capital ₹ 9.44 M
as on 22-12-2024
- Company Age 19 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 M
as on 22-12-2024
- Revenue -59.07%
(FY 2020)
- Profit -292.00%
(FY 2020)
- Ebitda -362.70%
(FY 2020)
- Net Worth -19.95%
(FY 2020)
- Total Assets -22.01%
(FY 2020)
About Hextar Pharmaceuticalss
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.44 M.
The company currently has active open charges totaling ₹1.50 M.
Anbazhagan and Kannan serve as directors at the Company.
- CIN/LLPIN
U24232TN2005PTC055692
- Company No.
055692
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hextar Pharmaceuticalss?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anbazhagan  | Managing Director | 17-Mar-2005 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kannan | Director | 17-Mar-2005 | Current |
Financial Performance of Hextar Pharmaceuticalss.
Hextar Pharmaceuticalss Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 59.07% decrease. The company also saw a substantial fall in profitability, with a 292% decrease in profit. The company's net worth observed a substantial decline by a decrease of 19.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hextar Pharmaceuticalss?
In 2019, Hextar Pharmaceuticalss had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Inforios Software Technologies India Private LimitedActive 12 years 7 monthsAnbazhagan is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 14 Dec 2007 | ₹0.50 M | Open |
State Bank Of India Creation Date: 14 Dec 2007 | ₹0.50 M | Open |
State Bank Of India Creation Date: 14 Dec 2007 | ₹0.50 M | Open |
How Many Employees Work at Hextar Pharmaceuticalss?
Unlock and access historical data on people associated with Hextar Pharmaceuticalss, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hextar Pharmaceuticalss, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hextar Pharmaceuticalss's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
